Biochemical markers for prostatic carcinoma
Fair, W.R.
Progress in Clinical and Biological Research 239: 659-680
1987
ISSN/ISBN: 0361-7742 PMID: 2443916 Document Number: 299225
Document emailed within 1 workday
Related Documents
Kuroda, I.; Ueno, M. 2009: Biochemical markers of bone turnover. new aspect. Bone metabolic markers in prostatic carcinoma Clinical Calcium 19(8): 1170-1177Leńko, J.; Marczyńska, A.; Kulpa, J.; Kwinta, A.; Bugajski, A. 1986: Biochemical control investigations (determinations of prostatic phosphatase--carcinoembryonic antigen alkaline phosphatase) in patients treated for prostatic carcinoma. Preliminary estimation of effectiveness Materia Medica Polona. Polish Journal of Medicine and Pharmacy 18(4): 238-243
Hiraoka, Y.; Sa, I. 2002: Biochemical diagnosis of benign prostatic hyperplasia (including differential diagnosis with prostatic carcinoma) Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 11): 342-345
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Kumamoto, Y.; Tsukamoto, T.; Umehara, T.; Harada, M.; Shimazaki, J.; Fuse, H.; Oshima, H.; Takeuchi, H.; Yoshida, O.; Okada, K. 1990: Clinical studies on endocrine therapy of prostatic carcinoma (3): Histopathological features of prostatic carcinoma and its prognosis Hinyokika Kiyo. Acta Urologica Japonica 36(3): 295-305
Svanholm, H.; Hørder, M. 1988: Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques Scandinavian Journal of Urology and Nephrology. Supplementum 107: 65-70
Yamauchi, M. 2009: Biochemical markers of bone turnover. new aspect. Biochemical bone markers of bone in patients treated with glucocorticoid Clinical Calcium 19(8): 1092-1100
Lowe, F.C.; Isaacs, J.T. 1984: Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model Cancer Research 44(2): 744-752
Kanoh, Y. 2011: Biochemical markers and physiological tests of atherosclerosis--changes and usefulness of markers in anti-atherosclerotic therapy Rinsho Byori. Japanese Journal of Clinical Pathology 59(1): 80-88
Weinberg, D.S.; Weidner, N. 1993: Concordance of DNA content between prostatic intraepithelial neoplasia and concomitant invasive carcinoma. Evidence that prostatic intraepithelial neoplasia is a precursor of invasive prostatic carcinoma Archives of Pathology and Laboratory Medicine 117(11): 1132-1137
Shimazaki, J.; Fuse, H.; Akimoto, S.; Sumiya, H.; Akakura, K.; Ichikawa, T. 1988: Prostatic carcinoma. I: Androgen dependency of prostatic carcinoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(4 Pt: 2-1): 909-916
Sáenz de Chirife, A.M.; Bassi, A.M.; Celeste, F.; Bergdolt, D. 1991: Specific prostatic antigen in prostatic carcinoma: its relationship with tumor differentiation and clinical course Archivos Espanoles de Urologia 44(4): 405-409
Strohmenger, P. 1980: Prostatic adenoma--prostatic carcinoma. Questions from general practice. II. Therapy Zfa. Zeitschrift für Allgemeinmedizin 56(28): 1793-1797
Pretlow, T.G.; Whitehurst, G.B.; Pretlow, T.P.; Hunt, R.S.; Jacobs, J.M.; McKenzie, D.R.; McDaniel, H.G.; Hall, L.M.; Bradley, E.L. 1982: Decrease in creatine kinase in human prostatic carcinoma compared to benign prostatic hyperplasia Cancer Research 42(11): 4842-4848
Bologna, M.; Festuccia, C.; Vicentini, C.; Muzi, P.; Biordi, L.; De Nicola, G.; Ventura, T. 1991: Establishment and characterization of a human prostatic carcinoma cell strain obtained from exfoliated tumor cells after prostatic massage Tumori 77(1): 70-75
Abdalla, A.M.; Oliver, J.A. 1971: SV40 virus transformed prostatic carcinoma in the hamster. I. Comparisons of lactate dehydrogenase isoenzymes with human prostatic cancer Investigative Urology 8(4): 442-447
Shiran, M.S.; Tan, G.C.; Sabariah, A.R.; Rampal, L.; Phang, K.S. 2007: P63 as a complimentary basal cell specific marker to high molecular weight-cytokeratin in distinguishing prostatic carcinoma from benign prostatic lesions Medical Journal of Malaysia 62(1): 36-39
Maygarden, S.J.; Strom, S.; Ware, J.L. 1992: Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia Archives of Pathology and Laboratory Medicine 116(3): 269-273
Schubert, J.; Gorski, J. 1983: Zum biologischen Verhalten des Prostatakarzinoms. II: Klinisch-operative Studien zur lymphogenen Metastasierung des Prostatakarzinoms - Le comportement biologique du cancer prostatique. II: Etudes clinicochirurgicales sur les métastases lymphogènes du cancer prostatique - Biological behaviour of prostatic carcinoma. II. Clinical operative studies of lymphatic metastasizing of prostatic carcinoma der Urologe. Ausgabe a 22: 356-359
Fuse, H.; Umeda, K.; Kazama, T.; Sakamoto, M.; Sakai, T.; Fujishiro, Y.; Mizuno, I.; Katayama, T. 1991: Relationship between reactivation and tumor markers in prostatic cancer Hinyokika Kiyo. Acta Urologica Japonica 37(1): 39-43